Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2017

View Archived Issues

EMA grants SPK-9001 access to PRIME program for hemophilia B

Melinta and Menarini sign development and commercialization agreement for delafloxacin

EMA grants orphan drug designation to Resolaris for limb girdle muscular dystrophy

Theratechnologies acquires commercial rights to ibalizumab in E.U. and other countries

C5aR1 as a potential new therapeutic target in Gaucher disease

FDA approves Noctiva for nocturnal polyuria

Chemotherapy-induced pyrimidine synthesis provides a target for triple-negative breast cancer

Santen Pharmaceutical and Singapore Eye Research Institute launch 5-year ophthalmic collaboration

PRC2 and BET bromodomain proteins as therapeutic targets for diffuse intrinsic pontine gliomas

Amryt completes phase III discussions with FDA and EMA for AP-101 in epidermolysis bullosa

Phase I study of Lymfactin advances to highest dose level

Cabozantinib S-malate from Exelixis granted U.S. orphan drug designation for the treatment of HCC

Vernalis and Servier establish new 2-year oncology drug discovery collaboration

TiGenix updates progress of European MAA procedure for Cx-601

Genetic analyses of phase II studies of Qbeco in Crohn's disease and ulcerative colitis

FORUM Pharmaceuticals discloses novel CHRNA7 agonists

Incyte identifies new TAM kinase inhibitors

U.S. Dept. of Health & Human Services patents thioredoxin reductase inhibitors

Memorial Sloan-Kettering presents novel Mcl-1 inhibitors

Zafgen discovers methionine aminopeptidase 2 inhibitors

The Broad Institute patents anti-mycobacterial compounds

Angsana to provide Asian diagnostic screening for STARTRK-2 trial of entrectinib

Phase I results presented for ANB-020

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...